-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Proprotein convertase subtilisin 9 (PCSK9) inhibitor is a promising lipid-lowering drug, although its use is limited by cost.
Recently, the medsci.
medsci.
The researchers determined from the third quarter of 2015 to the second quarter of 2019, the US Food and Drug Administration the number of Board approved start using the PCSK9 inhibitors ASCVD patients.
Manage cholesterol
Researchers identified 126,419 ASCVD patients who were treated with PCSK9 inhibitors or statins.
It can be seen that although there is more and more evidence of efficacy trials, the guidelines recommend the use of PCSK9 inhibitors in high-risk ASCVD patients, but from 2015 to 2019, very few patients started to use PCSK9 inhibitors.
Although there is increasing evidence of efficacy trials and guidelines recommend the use of PCSK9 inhibitors in high-risk ASCVD patients, from 2015 to 2019, few patients started using PCSK9 inhibitors.
Original source:
Elias J.
